Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Andreas Hettich GmbH & Co. KG has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are being handled by 2 distinct examiners, meaning each examiner is responsible for one pending matter. This distribution indicates that the company's current applications are receiving separate reviews from different individuals, even within the same technology sector.
The company's current prosecution is concentrated in 1 distinct art unit. CHARLES E COOLEY is the busiest examiner for the portfolio, overseeing 1 pending office action. This data shows that while the art unit is centralized, the individual examiners assigned to the 2 pending office actions are distinct. The focus on a single art unit suggests that the company's current Biotechnology & Pharmaceuticals applications are technically similar or closely related in subject matter.
Having 2 distinct examiners in 1 distinct art unit provides a unique prosecution environment. Practitioners can expect consistent art unit policies but must adapt to the different examination styles of the 2 examiners involved. Since CHARLES E COOLEY is one of the 2 examiners and handles 1 of the 2 pending actions, his specific approach will be a key factor in the company's success for that particular application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ISMAIL, REHANA | 1 | 75.8% | +34.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996370 | PHOSPHOLIPIDS AND PHOSPHOLIPID METABOLITES FOR TREATING VIRAL AND BACTERIAL PNEUMONIA AND SEPSIS | ISMAIL, REHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996370 | PHOSPHOLIPIDS AND PHOSPHOLIPID METABOLITES FOR TREATING VIRAL AND BACTERIAL PNEUMONIA AND SEPSIS | ISMAIL, REHANA | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17996370 | PHOSPHOLIPIDS AND PHOSPHOLIPID METABOLITES FOR TREATING VIRAL AND BACTERIAL PNEUMONIA AND SEPSIS | ISMAIL, REHANA | 1625 | §103§112 | Non-Final OA | — | Pending | Jun 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial